$3.29
2.37% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Protara Therapeutics Inc Stock price

$3.29
+0.02 0.61% 1M
-2.96 47.36% 6M
-1.99 37.69% YTD
+0.55 20.07% 1Y
-25.69 88.65% 5Y
-674.31 99.51% 10Y
-397.91 99.18% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.08 2.37%
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Key metrics

Market capitalization $126.93m
Enterprise Value $2.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.81
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-51.00m
Free Cash Flow (TTM) Free Cash Flow $-41.10m
Cash position $124.36m
EPS (TTM) EPS $-1.10
P/E forward negative
Short interest 5.97%
Show more

Is Protara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Protara Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Protara Therapeutics Inc forecast:

Buy
100%

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
1% 1%
-
- Research and Development Expense 33 33
20% 20%
-
-51 -51
11% 11%
-
- Depreciation and Amortization 0.33 0.33
3% 3%
-
EBIT (Operating Income) EBIT -51 -51
11% 11%
-
Net Profit -46 -46
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protara Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therape...
Neutral
GlobeNewsWire
30 days ago
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Neutral
GlobeNewsWire
about one month ago
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office United States
CEO Jesse Shefferman
Employees 31
Founded 2006
Website protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today